Core Viewpoint - Beihai Kangcheng-B (01228) reported a significant decrease in revenue for the six months ending June 30, 2025, with earnings of 22.248 million, a year-on-year decline of 50.33% [1] Financial Performance - The company achieved a profit of 59.238 million, contrasting with a loss of 247 million in the same period last year [1] - Earnings per share stood at 0.14 yuan [1] Revenue Drivers - The revenue decline is primarily attributed to the company's strategic focus on rare diseases initiated in 2021, leading to the cessation of sales of He Li An in Taiwan after the distribution agreement ends in late 2024 [1] - Excluding the sales of He Li An in Taiwan, revenue decreased by 1.7 million or 6.9% compared to the same period in 2024 [1] - The company implemented proactive inventory management in the first half of 2025, resulting in reduced inventory levels of Mai Ru Bei in the distribution channels [1]
北海康成-B发布中期业绩，期内溢利5923.8万元 同比扭亏为盈